Friday, 20 November 2026
Companies

Arcera Life Sciences licenses Innogen's GLP-1 therapy for key markets

The Abu Dhabi firm will handle regulatory activities, market access and commercialisation of Efsubaglutide Alfa across Africa, Eastern Europe, Latin America and the Middle East, including the UAE.

Group of executives posing together in front of Arcera branded backdrop
Photo · Arcera Life Sciences

Arcera Life Sciences has signed an exclusive licensing and commercialisation agreement with Innogen Pharmaceuticals for Efsubaglutide Alfa, a GLP-1 receptor agonist therapy, covering international markets including the UAE, the companies said on 19 November.

Under the deal, Arcera, which is headquartered in Abu Dhabi, will take on regulatory activities, market access and commercial roll-out of the therapy in agreed territories across selected countries in Africa, Eastern Europe, Latin America and the Middle East. Innogen, a Shanghai-based biopharmaceutical company focused on metabolic diseases, will receive an upfront payment and stands to earn milestone payments plus tiered royalties on net sales in the licensed territories.

The companies said the agreement makes cardiometabolic disease a core part of Arcera’s portfolio, pairing Innogen’s work in metabolic diseases with Arcera’s regulatory, market access and commercial reach.

Trial results

Innogen describes Efsubaglutide Alfa as a fusion protein combining a human GLP-1 analogue with an IgG Fc fragment, giving it a half-life of up to 280 hours across different studies. Innogen reported HbA1c reductions of approximately 2.2 percentage points at Week 24 in its clinical studies.

According to Innogen, trials in Chinese adults with overweight or obesity found that 18 weeks of treatment produced average weight reductions of 10.6% with once-weekly dosing and 9.7% with once-every-two-weeks dosing. The same studies, Innogen said, recorded a muscle-to-fat ratio increase of up to 45.3% from baseline with once-weekly dosing and a reduction in liver fat content of up to 51.8% on that schedule, with no participants discontinuing treatment due to adverse events during the 18-week period.

Innogen has also completed a Phase II trial in Australia in adults with overweight or obesity, testing once-monthly dosing, which the company said adds further clinical evidence ahead of the product’s planned global registration and commercialisation.

Isabel Afonso, chief executive officer of Arcera Life Sciences, said: “Our agreement with Innogen accelerates the bridge we are building between China and our international markets to bring innovative medicines to more patients and strengthen our cardiometabolic portfolio.”

Dr Qinghua Wang, founder, chairman and chief executive officer of Innogen Pharmaceuticals, said: “By combining Innogen’s scientific innovation with Arcera’s strengths in international regulatory affairs and commercialization, we aim to broaden access to differentiated therapies and ultimately improve the quality of life of patients around the world.”

The transaction is subject to customary regulatory and operational requirements in the relevant territories, and commercialisation will begin once local regulatory approvals are obtained.

The photo above was issued by Arcera Life Sciences with the announcement.